Hantavirus Economic Burden

The Data Gap: Why No Aggregate Figure Exists

For most major infectious diseases, health economists can produce an annual U.S. burden estimate — total cases multiplied by per-case cost, plus productivity losses and premature death — based on surveillance data and cost-of-illness methodology. For hantavirus pulmonary syndrome (HPS), this calculation is not straightforward for three reasons:

1. Small case numbers. The CDC has recorded fewer than 900 confirmed HPS cases in the United States since 1993. Annual case counts typically number in the single digits to low tens — too small for the statistical averaging that cost-of-illness studies require.
2. Extreme case heterogeneity. Outcomes range from rapid death to full recovery, with wide variation in ICU length of stay, ECMO use, and complications. Per-case cost variance is very high, making aggregate estimates unreliable without large samples.
3. Limited research funding. Cost-of-illness studies are expensive to conduct and are typically funded when a disease's burden justifies the investment. The low incidence of HPS, despite its severity, has not historically attracted the research infrastructure that produces burden estimates.

This page does not invent a figure where none exists. Instead, it describes what is known about the economic character of hantavirus disease — information that is useful precisely because it differs from the aggregate-cost framing used for other diseases.

How Small Is "Small"? The Actual Case Counts

The first reason above deserves numbers, because "too few cases for cost-of-illness methodology" is a claim that can be checked. Here is the denominator a burden estimate would have to work with.

The arithmetic that tempts people is straightforward and that is exactly the problem. Thirty cases a year multiplied by a per-case cost drawn from a range spanning an order of magnitude produces a number with an implied precision the inputs cannot support — and, once published, that number gets cited as though it were measured. We show the inputs instead, and let the reader see how wide the interval would have to be.

Per-Case Cost: Catastrophic by Any Measure

Individual cases of hantavirus pulmonary syndrome that progress to the cardiopulmonary phase are among the most resource-intensive acute illnesses in U.S. medicine. HPS is also unusually lethal: the CDC reports that 38% of people who develop respiratory symptoms die from the disease — so the costs below are incurred on top of a high probability of death, not in exchange for a reliable recovery. The economic character of a severe HPS case includes:

Intensive ICU care

Patients who develop severe HPS require ICU admission for hemodynamic monitoring, oxygen support, and management of cardiogenic shock. ICU costs are concentrated early in the stay: a widely cited multi-hospital U.S. analysis (Dasta et al., Critical Care Medicine, 2005) found that daily ICU costs are highest during the first two days of admission and that mechanical ventilation alone adds roughly $1,500 per day. Severe HPS routinely involves days to weeks of ventilated intensive care, so the ICU component of a single case commonly reaches tens of thousands of dollars before any advanced life support is added.

Extracorporeal membrane oxygenation (ECMO)

For patients in refractory cardiopulmonary failure, ECMO — a form of mechanical heart-lung bypass — is the primary life-support intervention. ECMO is among the most expensive acute interventions in medicine: a systematic review of U.S. and international in-hospital ECMO costs found totals ranging from roughly $42,000 to $538,000 per case (2013 values), and more recent U.S. venovenous-ECMO series report median hospitalization costs above $250,000. There is no approved antiviral treatment for hantavirus; supportive care including ECMO is the only intervention available, per the CDC.

No approved treatment or vaccine

The absence of targeted antiviral therapy or a prophylactic vaccine means there is no way to shorten illness duration or reduce ICU resource utilization once a patient progresses to severe disease. This is not unique to hantavirus, but it is a key economic distinguishing factor: diseases with effective treatments allow early intervention to reduce cost and severity; HPS does not.

What the published cost inputs actually are

The two cost components that dominate a severe HPS admission — intensive care and ECMO — have published, citable ranges. Neither was produced for hantavirus specifically, which is itself part of the point.

Our calculation, shown so it can be checked. Take the ECMO review's midpoint of roughly $290,000 per course, and note that in the New Mexico series 51 patients were treated over sixteen years — about three a year nationally at the country's most experienced centre. That is on the order of $900,000 a year of ECMO spend for the whole United States, and the interval around it spans from about $128,000 to $1.6 million depending only on which end of the published cost range in Harvey et al. (Applied Health Economics and Health Policy, 2015) you pick. We are not publishing that as a burden estimate. We are showing it because seeing the width of the interval is the fastest way to understand why no credible aggregate figure exists.

Long recovery and rehabilitation

Survivors of severe HPS frequently require extended convalescence, physical rehabilitation, and follow-up pulmonary care. The productivity losses from weeks or months off work — for a disease that disproportionately strikes working-age adults — are material at the individual level even if they do not register at the aggregate economic level.

Rural and Occupational Concentration

Hantavirus pulmonary syndrome is not randomly distributed across the U.S. population. Its economic impact is concentrated in specific communities and industries:

• Rural western states. The Four Corners region (Arizona, Colorado, New Mexico, Utah) and other rural western states account for the majority of U.S. HPS cases — CDC reports 94% of cases occur west of the Mississippi River, per CDC reported-case data. These communities are geographically distant from the tertiary care centers — often major urban academic medical centers — that have ECMO capability, creating transport and transfer costs on top of ICU costs.
• Agricultural and outdoor workers. Exposure occurs through contact with infected rodents, primarily deer mice (Peromyscus maniculatus). Farm workers, ranchers, campers, and people engaged in cleaning cabins, barns, or sheds are at highest risk. The age distribution makes this an economic question rather than only a clinical one: CDC's registry gives a median patient age of 38 and CDC's surveillance analysis found most cases in people aged 20 to 50, with a case-fatality rate that does not fall with youth — it is statistically flat across every age band from 10 to 70-plus. When a working-age agricultural worker requires weeks of ICU care and months of recovery, the economic impact on a small family farm or rural business is severe at the household level, and it falls on people at peak earning age.
• Native American communities. CDC's registry records 19% of confirmed hantavirus cases in American Indian or Alaska Native patients, a group that is roughly 1% of the U.S. population. CDC's own analysis of exposure characteristics from 1993 to 2015 identified those at highest risk as people in occupations with rodent exposure and American Indian women aged 40–64 (de St Maurice et al., Emerging Infectious Diseases, 2017). The economic consequence compounds an existing health-equity disparity: the populations most affected are also the furthest from the tertiary centres where the expensive care is delivered.

What Honest Economic Analysis Looks Like for a Rare Disease

The hantavirus case illustrates a broader principle in health economics: the absence of an aggregate economic burden estimate does not mean a disease has no economic burden. It means the disease is rare enough that the research infrastructure for burden estimation has not been deployed.

For rare, severe diseases like HPS, the economically relevant questions are different from those asked of common diseases:

• What is the cost to the health system and family of a single severe case?
• Which specific communities and industries bear a disproportionate share of that cost?
• What would prevention cost, relative to treatment? (Rodent-proofing a building costs far less than an ECMO course.)
• How does the cost of maintaining surveillance and outbreak-response capacity compare to the cost of missing an outbreak that grows?

These are the economically tractable questions for hantavirus. Producing a spurious aggregate figure by multiplying unverified per-case costs by case counts would suggest more precision than the data support — and would likely be cited uncritically in subsequent analyses. This page declines to do that.

What prevention costs, relative to treatment

The third question above is the one with a usable answer, and it is the strongest economic argument in the whole subject. CDC's cleanup protocol requires a respirator, gloves, bleach, paper towels and disposal bags — the supply cost is on the order of tens of dollars, and our cleanup cost page puts a full DIY kit at roughly $50–90. Professional remediation of a contaminated attic or crawlspace runs into the low thousands. A single ECMO course, at the published midpoint, is roughly $290,000 — with a 40% chance the patient dies anyway.

Our calculation: at the published ECMO midpoint of about $290,000 per course, one avoided severe case pays for roughly 3,200 DIY cleanup kits at $90 each, or around 145 professional remediations at $2,000. The ratio is so lopsided that it does not depend on the precision of either input — which is exactly the property a rare-disease economic argument needs, and exactly why "buy the N95 before you open the cabin" is a defensible economic statement where "hantavirus costs the U.S. $X million a year" is not.

What the surveillance capacity question looks like in practice

The fourth question — what surveillance costs against what missing an outbreak costs — got an unusually clear illustration in 2026. The MV Hondius Andes virus cluster involved 13 cases and 3 deaths, and the response that contained it ran contact tracing in 33 countries and overseas territories, put 317 high-risk contacts through 42 days of quarantine and 336 low-risk contacts through self-monitoring, evacuated and repatriated a ship's complement, and generated four separate technical guidance documents and a 21-country prospective study (WHO, Disease Outbreak News, 2 July 2026). Nobody has published the cost of that response, and we will not estimate it. What can be said is that the ratio of response effort to case count was extraordinary, and that the outbreak produced no secondary case off the ship. Both facts belong in any honest assessment of what preparedness capacity is worth.

Compared to what? For where hantavirus sits against other viruses on severity and frequency together — the two axes any economic framing has to hold at once — see the network's Virus Risk Perspective and this site's hantavirus risk snapshot.

What is not known

To be explicit about the boundaries of this page: there is no published U.S. cost-of-illness study for hantavirus, no hantavirus-specific ECMO cost series, no published cost for the 2026 international outbreak response, and no measurement of indirect costs — lost earnings, caregiver time, the financial effect on a small rural business when its operator is hospitalised for three weeks. Each of those is a real cost and none of them has a number. The page states this rather than filling the gaps, because in a field this small a fabricated figure would likely become the figure.

Sources & References

• CDC. About Hantavirus (38% case-fatality rate once respiratory symptoms develop). cdc.gov/hantavirus/about
• CDC. Hantavirus Pulmonary Syndrome (HPS). cdc.gov/hantavirus/hps
• CDC. Reported Cases of Hantavirus Disease (890 U.S. cases, 1993–2023; 94% west of the Mississippi). cdc.gov/hantavirus/data-research/cases
• Dasta JF, McLaughlin TP, Mody SH, Piech CT. Daily cost of an intensive care unit day: the contribution of mechanical ventilation. Crit Care Med. 2005. PubMed 15942342
• Harvey MJ, Gaies MG, Prosser LA. U.S. and International In-Hospital Costs of Extracorporeal Membrane Oxygenation: a Systematic Review. Appl Health Econ Health Policy. 2015;13(4):341–357 (total in-hospital ECMO costs $42,554–$537,554 in 2013 values, across 18 studies). doi:10.1007/s40258-015-0170-9 · PubMed 25894740
• Dietl CA, Wernly JA, Pett SB, et al. Extracorporeal membrane oxygenation support improves survival of patients with severe Hantavirus cardiopulmonary syndrome. J Thorac Cardiovasc Surg. 2008;135(3):579–584 (38 patients; 60.5% survival; mean stay 20.8 days; mean run 132 hours). doi:10.1016/j.jtcvs.2007.11.020 · PubMed 18329474
• Wernly JA, Dietl CA, Tabe CE, et al. Extracorporeal membrane oxygenation support improves survival of patients with Hantavirus cardiopulmonary syndrome refractory to medical treatment. Eur J Cardiothorac Surg. 2011;40(6):1334–1340 (51 patients over sixteen years at one centre). doi:10.1016/j.ejcts.2011.01.089 · PubMed 21900022
• MacNeil A, Ksiazek TG, Rollin PE. Hantavirus pulmonary syndrome, United States, 1993–2009. Emerg Infect Dis. 2011;17(7):1195–1201 (11–48 cases a year; 0.04–0.19 per million; case-fatality flat across age bands). doi:10.3201/eid1707.101306 · PubMed 21762572
• de St Maurice A, Ervin E, Schumacher M, et al. Exposure Characteristics of Hantavirus Pulmonary Syndrome Patients, United States, 1993–2015. Emerg Infect Dis. 2017;23(5):733–739. doi:10.3201/eid2305.161770 · PubMed 28418312
• CDC. NNDSS Weekly Data (provisional annual hantavirus counts for 2024–2026; rows updated September 9, 2026). data.cdc.gov dataset x9gk-5huc
• World Health Organization. Disease Outbreak News: Hantavirus outbreak linked to cruise ship travel, Multi-locations, 2 July 2026 (scale of the international response: 33 countries and territories, 317 high-risk and 336 low-risk contacts, four technical guidance documents, 21-country prospective study). who.int/emergencies

Related Topics

• Hantavirus Symptoms: Phases and Progression
• How Hantavirus Spreads
• Hantavirus Prevention: Rodent Control and Exposure Reduction
• Pandemic Economic Impact: Cross-Disease Overview